Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

SELL
$137.6 - $154.97 $10,457 - $11,777
-76 Reduced 5.74%
1,249 $193,000
Q3 2023

Nov 14, 2023

SELL
$133.59 - $154.65 $467,431 - $541,120
-3,499 Reduced 72.53%
1,325 $197,000
Q2 2023

Aug 11, 2023

SELL
$132.51 - $164.9 $790,157 - $983,298
-5,963 Reduced 55.28%
4,824 $649,000
Q1 2023

May 12, 2023

SELL
$144.61 - $166.54 $33,115 - $38,137
-229 Reduced 2.08%
10,787 $1.72 Million
Q4 2022

Feb 13, 2023

BUY
$138.31 - $165.87 $159,748 - $191,579
1,155 Added 11.71%
11,016 $1.78 Million
Q3 2022

Nov 14, 2022

SELL
$134.21 - $153.93 $201,315 - $230,895
-1,500 Reduced 13.2%
9,861 $1.32 Million
Q2 2022

Aug 12, 2022

BUY
$137.62 - $174.96 $103,627 - $131,744
753 Added 7.1%
11,361 $1.74 Million
Q1 2022

May 13, 2022

SELL
$131.98 - $163.75 $23,096 - $28,656
-175 Reduced 1.62%
10,608 $1.72 Million
Q4 2021

Feb 14, 2022

BUY
$107.43 - $135.93 $518,994 - $656,677
4,831 Added 81.17%
10,783 $1.46 Million
Q3 2021

Nov 12, 2021

BUY
$106.4 - $120.78 $55,860 - $63,409
525 Added 9.67%
5,952 $642,000
Q1 2021

May 14, 2021

BUY
$102.3 - $112.62 $89,614 - $98,655
876 Added 19.25%
5,427 $587,000
Q4 2020

Feb 12, 2021

BUY
$80.49 - $108.67 $259,097 - $349,808
3,219 Added 241.67%
4,551 $487,000
Q3 2020

Nov 12, 2020

SELL
$85.91 - $100.83 $27,233 - $31,963
-317 Reduced 19.22%
1,332 $117,000
Q2 2020

Aug 13, 2020

SELL
$73.37 - $98.18 $440 - $589
-6 Reduced 0.36%
1,649 $162,000
Q1 2020

May 14, 2020

SELL
$64.5 - $97.79 $50,826 - $77,058
-788 Reduced 32.26%
1,655 $126,000
Q4 2019

Feb 14, 2020

BUY
$72.13 - $90.25 $54,818 - $68,590
760 Added 45.16%
2,443 $216,000
Q3 2019

Nov 13, 2019

BUY
$62.98 - $75.72 $9,572 - $11,509
152 Added 9.93%
1,683 $127,000
Q1 2019

May 15, 2019

BUY
$77.14 - $90.79 $35,175 - $41,400
456 Added 42.42%
1,531 $123,000
Q4 2018

Feb 14, 2019

BUY
$77.85 - $96.01 $83,688 - $103,210
1,075 New
1,075 $99,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Mirova Portfolio

Follow Mirova and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirova, based on Form 13F filings with the SEC.

News

Stay updated on Mirova with notifications on news.